LONDON, Feb. 5, 2013 /PRNewswire/ -- Stanmore Implants ('Stanmore'), specialists in the design and manufacture of patient specific and modular orthopaedic implants, announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its Sculptor Robotic Guidance Arm ("Sculptor RGA") for precision implant placement in unicompartmental knee surgery, also known as partial knee resurfacing.
Partial knee resurfacing only replaces the parts of the knee that are worn out and painful rather than cutting away the entire joint This preservation technique retains the natural ligaments around the knee, reduces surgical damage to tissue and is less invasive compared to total knee replacement. Sculptor RGA utilises a robotic guidance arm to assist the surgeon's operation of a cutting tool, limiting the removal of bone to a pre-defined safe area using Stanmore's patent protected 'Active Constraint' technology.
Stanmore's unique personalised procedural approach to surgery seamlessly integrates advanced technologies. From proprietary planning software, personalised implants are designed in-house, then manufactured and placed precisely. During surgery, bone is removed corresponding to the implant shape whilst a tracking arm determines and monitors the location of the patient ensuring that the surgeon accurately prepares the bone surface to match the implant precisely.
This new and unique approach to the treatment of osteoarthritis of the knee has been used at a number of leading centres in the UK since the first patient specific personalised knee was implanted in July 2011 and builds upon the earlier clinical work undertaken using the Active Constraint technology featured in the Sculptor RGA device. Active Constraint technology has been shown to provide better functional outcome at 7 year follow up for partial knee surgery compared to the saws and jigs currently used in most knee surgery procedures, which are prone to a much higher degree of placement error.
The Sculptor RGA will be introduced in the United States for unicompartmental knee surgery in a limited release to a select group of surgeons from mid-2013, as Stanmore continues its evidence based approach to new product introduction. The Company is also developing additional applications for Sculptor RGA with the goal of broader commercialisation next year.
Brian Steer, Executive Chairman of Stanmore, said:
"Following this FDA clearance for Sculptor RGA we are excited by the opportunity to bring our personalised approach to knee surgery to patients in the United States. Robotic technology represents a major advance in orthopaedics, providing accurate placement that is critical to implant longevity and reproducibility along with tangible cost benefits, making access to robotic surgery more widely available to patients. Stanmore is now looking forward to working further with surgeons to continue to develop innovative solutions for the global orthopaedic market."
Stanmore Implants Worldwide
Tel: +44 (0)20 8238 6500
Graeme Brookes (Managing Director - Primary Orthopaedics)
Eric Dodd (CFO)
Brian Steer (Executive Chairman)
Tel: +44 (0) 20 7831 3113
Ben Atwell, Stephanie Cuthbert, Mo Noonan
Robert Stanislaro, Brian Ritchie
Tel: (646) 576-8100
Notes to Editors
Stanmore Implants is an innovative orthopaedic business focused on the design, manufacture and commercialisation of patient specific primary implants and implants to provide solutions for extreme orthopaedic cases, including limb sparing, complex primary and revision joint replacement. Stanmore's implant design service alongside its portfolio of orthopaedic implants draws on over 60 years' experience in providing some of the world's most successful implants.
By combining Sculptor RGA technology with patient specific partial knee implants, Stanmore's goal is to provide surgeons with a bone conserving solution that is personalised for the patient, is affordable and offers clinical benefits and cost effectiveness versus current treatment options. Initially, the Sculptor RGA is approved for use in unicompartmental knee replacement, a global market estimated to be 150,000 procedures per year with a market value of approximately $450 MM.
Stanmore is backed by leading investors including Abingworth, Imperial Innovations and Ivy Capital and intends to seek like-minded co-investors in 2013 to further support the commercialisation and growth opportunities offered by its unique technologies and market positioning.
For further information visit www.stanmoreimplants.com
SOURCE Stanmore Implants